SEC Form 4 · accession 0001867096-26-000073
Xeris Biopharma Holdings, Inc. · XERS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Patrick Shannon Jr.
Officer — See Remarks · Director
Period of report
Aug 1, 2026
Accepted (ET)
Aug 21, 2026 · 4:23 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001867096
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 1, 2026 | F | 36,645 | $8.08 | D | 2,898,933 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2026.
Remarks
Chief Executive Officer and Chairman of the Board